구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | ||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Columvi (glofitamab) | Epkinly (epcoritamab) | Kymriah (tisagenlecleucel) | Obinutuzumab |
Overview Company | Roche / Genentech | Roche / Genentech | Genmab / AbbVie | Novartis | Roche / Genentech |
Overview Modality | ADC | ANTIBODY | ANTIBODY | CGT | ANTIBODY |
Overview Target | FRα | CD20 × CD3 | CD20 × CD3 | CD19 | B-cell Lymphoma |
Overview Indication | Large B-Cell Lymphoma | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | ALL, DLBCL, FL | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | PHASE_3 | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | RECRUITING | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | 4-1BB persistence profile | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr |
Positioning Known limitation | resistance to POLA in vivo | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | downregulation of naïve T-cell-associated genes (SELL and CD28) | resistance to treatment |
Positioning Development positioning | — | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
Technology Vector | — | — | — | Lentivirus | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | targets type I interferon signaling |
MoA Biomarker | CD20 expression | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD19; measurable residual disease in ALL. | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets |
PK/PD Half-life | 12.2 h | ~1–2 weeks | ~3 weeks at steady state | — | — |
PK/PD Species | Rat | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | NHP, CAR T transgene persistence, B-cell aplasia | Cynomolgus monkey, Macaque, Mouse |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP | Human, NHP, In vitro | NHP, In vitro | Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic | Pharmacodynamic | pharmacokinetic | pharmacodynamic | Pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey | NHP, Mouse | Cynomolgus monkey, Macaque, Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | Human | Mouse, NHP, Monkey |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | thrombocytopenia or organ dysfunction, were documented |
Toxicology CRS | — | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | Reported |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | thrombocytopenia or organ dysfunction, were documented |
Clinical Selected reported efficacy | ORR 100% | ORR 35.3% | ORR 61% | — | ORR 100% |
Clinical Reported ORR | 100.0% | 35.3% | 61% (DLBCL) | — | 100.0% |
Clinical Reported OS | — | — | — | 0 | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_3 | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02611323 | NCT04313608 | NCT03625037 | NCT04225676 | NCT02611323 |
Preclinical Animal (cat.) | — | NHP | Human, NHP, Monkey, In vitro | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp) Genmab / AbbVie·CD20 × CD3 57 trials·t½ ~3 weeks at steady state | ||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Columvi (glofitamab) | Epkinly (epcoritamab) | Kymriah (tisagenlecleucel) | Obinutuzumab |
Overview Company | Roche / Genentech | Roche / Genentech | Genmab / AbbVie | Novartis | Roche / Genentech |
Overview Modality | ADC | ANTIBODY | ANTIBODY | CGT | ANTIBODY |
Overview Target | FRα | CD20 × CD3 | CD20 × CD3 | CD19 | B-cell Lymphoma |
Overview Indication | Large B-Cell Lymphoma | Relapsed or refractory diffuse large B-cell lymphoma | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma | ALL, DLBCL, FL | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | PHASE_3 | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | RECRUITING | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | Bivalent CD20 binding increases avidity; obinutuzumab pretreatment debulks circulating B cells to blunt first-dose CRS. | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. | 4-1BB persistence profile | novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces pr |
Positioning Known limitation | resistance to POLA in vivo | CD20 loss after prior anti-CD20 therapy and T-cell exhaustion. | CD20 antigen loss and exhausted effector T cells after multiple prior lines. | downregulation of naïve T-cell-associated genes (SELL and CD28) | resistance to treatment |
Positioning Development positioning | — | Competes with Epkinly on schedule and route; fixed duration is its main claim. | Main SC alternative to Columvi, with continuous rather than fixed duration. | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
Technology Vector | — | — | — | Lentivirus | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Crosslinks CD20 on malignant B cells with CD3 on T cells; the 2:1 geometry stabilizes the synapse and drives T-cell activation and B-cell lysis. | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. | Autologous T cells transduced with lentiviral vector encoding CD19-specific CAR with 4-1BB and CD3ζ signaling domains. Engages CD19+ B cells leading to proliferation and cytotoxicity. | targets type I interferon signaling |
MoA Biomarker | CD20 expression | CD20 expression; ctDNA clearance investigational. | CD20 expression; ctDNA MRD investigational. | CD19; measurable residual disease in ALL. | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets |
PK/PD Half-life | 12.2 h | ~1–2 weeks | ~3 weeks at steady state | — | — |
PK/PD Species | Rat | Cynomolgus monkey, B-cell depletion, cytokine profile, PET-CR | Cynomolgus monkey, Peripheral B-cell depletion, cytokine kinetics, PET response | NHP, CAR T transgene persistence, B-cell aplasia | Cynomolgus monkey, Macaque, Mouse |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP | Human, NHP, In vitro | NHP, In vitro | Mouse, NHP, Monkey |
PK/PD Experiment | pharmacokinetic | Pharmacodynamic | pharmacokinetic | pharmacodynamic | Pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey | NHP, Mouse | Cynomolgus monkey, Macaque, Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | Human | Mouse, NHP, Monkey |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | thrombocytopenia or organ dysfunction, were documented |
Toxicology CRS | — | CRS ~63%, grade ≥3 ~4% | CRS ~50%, grade ≥3 ~2.5% | CRS ~58–79% in ALL; Grade ≥3 CRS managed with tocilizumab per protocol | Reported |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for CRS. Neurologic events, infection, neutropenia, and tumor flare require monitoring. | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. | CRS and neurological events; hypogammaglobulinemia from B-cell aplasia. | thrombocytopenia or organ dysfunction, were documented |
Clinical Selected reported efficacy | ORR 100% | ORR 35.3% | ORR 61% | — | ORR 100% |
Clinical Reported ORR | 100.0% | 35.3% | 61% (DLBCL) | — | 100.0% |
Clinical Reported OS | — | — | — | 0 | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT04313608 | EPCORE NHL-1 (NCT03625037) | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_3 | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02611323 | NCT04313608 | NCT03625037 | NCT04225676 | NCT02611323 |
Preclinical Animal (cat.) | — | NHP | Human, NHP, Monkey, In vitro | — | — |
추천 비교
추천 비교